ABBV AbbVie Inc.
Company Analysis
Latest News
🔴 AbbVie is trading 3% down today amid a broad healthcare-sector selloff
AbbVie is trading 3% down at $248.68 after healthcare stocks came under pressure on September 8, 2026; the XLV sector ETF fell 2.19% during regular trading. -...
BofA Securities Raises AbbVie Price Target Following Apogee Deal
BofA Securities increased its price target for AbbVie (ABBV) to $282 from $276, maintaining a Buy rating. This adjustment followed AbbVie's acquisition of...
AbbVie’s Etentamig Cuts Myeloma Progression Risk by 60% in Phase 3 Trial
AbbVie reported positive topline results from the Phase 3 CERVINO trial for etentamig. The investigational treatment targets patients with relapsed or...
AbbVie Closes $10.9B Apogee Acquisition, Strengthening Immunology Pipeline
AbbVie completed its acquisition of Apogee Therapeutics for a total equity value of approximately $10.9 billion. Shareholders received $135.11 per share in...
AbbVie Seeks EU Approval for Subcutaneous SKYRIZI, Targeting Easier Crohn's Dosing
AbbVie submitted a regulatory application to the European Medicines Agency (EMA) for a subcutaneous (SC) induction option for SKYRIZI (risankizumab). The...
AbbVie Unveils Lung Cancer Data, Targeting Revenue Growth Beyond Immunology
AbbVie is presenting clinical and real-world data at the 2026 World Conference on Lung Cancer (WCLC). The presentations feature investigational programs...
AbbVie Lung Cancer Drug Hits 90% Response Rate in Early Trial
AbbVie presented new clinical data from its lung cancer research programs at the 2026 World Conference on Lung Cancer (WCLC). The company is developing a...
AbbVie's Obesity Drug Partner Gubra Reports Positive Phase 1 Data for Amylin Analog
Gubra A/S, a partner of AbbVie, announced encouraging topline data for ABBV-295. ABBV-295 is an amylin analog developed for obesity. The data comes from a...
🟢 AbbVie is trading 3.04% up today as healthcare stocks rally
AbbVie is trading 3.04% up at $266.79 as healthcare stocks rally, investors rotate toward defensive growth, and sector earnings outlooks improve. - No fresh...
🟢 AbbVie is trading 3.07% up today as healthcare stocks rally
AbbVie is trading 3.07% up at $258.02, with the move appearing primarily tied to healthcare-led sector rotation, not a new AbbVie-specific announcement. -...
AbbVie Target Raised to $300, Wells Fargo Eyes $6.5 Billion Drug Peak
Wells Fargo raised its price target for AbbVie Inc. to $300 from $295. The firm also reiterated its Overweight rating on the stock. Analysts identified...
AbbVie Upgraded to Outperform by Wolfe Research
Wolfe Research upgraded AbbVie Inc. The firm raised its rating to 'Outperform' from 'Peerperform'. It set a price target of $300. Canada recommended...
AbbVie Advances $10.9B Apogee Deal, Strengthening Immunology Pipeline After Vote
Apogee Therapeutics shareholders approved AbbVie’s planned acquisition of the company for approximately $10.9 billion. This vote clears a major hurdle for the...
AbbVie Announces $10.0 Billion Senior Notes Offering to Fund Apogee Acquisition
AbbVie Inc. has entered into an underwriting agreement to issue and sell nine series of senior notes with an aggregate principal amount of $10.0 billion. The...
AbbVie Beats on Revenue, Then Cuts Its Own Profit Forecast — Can a $10.9 Billion Bet on Eczema Justify Six Years of Thinner Earnings?
Shares slid 3.8% to $247.52 this morning after AbbVie delivered a strong Q2 beat but simultaneously trimmed its full-year profit outlook to absorb the cost of...
🔴 AbbVie is trading 3.8% down today after trimming profit outlook despite strong Q2 results
AbbVie is trading 3.8% down at $247.52 after trimming its 2026 profit outlook to fund a $10.9 billion acquisition of Apogee and accelerate pipeline...
AbbVie's second quarter revenue grew 10.2% to $16.99B, beating estimates on strong immunology franchise performance.
AbbVie reported second quarter net revenues of $16.99 billion, an increase of 10.2% year-over-year, while adjusted diluted EPS was $3.65, a 22.9% increase from...
🔴 AbbVie is trading 3.1% down today as investors position ahead of Q2 earnings
AbbVie is trading 3.1% down at $255.21 as investors position ahead of its Q2 2026 earnings report scheduled for July 31, 2026. • The price action suggests...
AbbVie Inc. Q2 2026 Earnings Preview: What Analysts Expect on July 31, 2026
AbbVie's Q2 2026 consensus revenue is $16.81 billion and EPS is $3.66, with shares recently trading at $265.52 against an average analyst target of...
AbbVie secures EU approval for Rinvoq, first systemic treatment for vitiligo
The European Commission approved AbbVie’s Rinvoq (upadacitinib) to treat non-segmental vitiligo in adults and adolescents aged 12 and older. This decision...